Clinical Trial

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 17, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic triple-negative breast cancer randomised to treatment with standard chemotherapy plus moxifloxacin or placebo.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-01-22; most recent amendment 2025-12-10.
Trial Details
NCT Number NCT04722978
Lead Sponsor Sun Yat-Sen University Cancer Center
Conditions Triple Negative Breast Cancer
Enrollment 228 participants
Start Date 2021-04-20
Primary Completion 2026-06 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-12-17